Sildenafil Citrate Powder, For Suspension
NDC Package 59651-420-11
Package Information
Sildenafil Citrate powders is adultsSildenafil for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)].Pediatric Patients (1 to 17 Years Old)Sildenafil for oral suspension is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14)]. This formulation utilizes a powder, for suspension delivery system. Marketed by Aurobindo Pharma Limited, this product is identified by NDC 59651-420 and is authorized under FDA application ANDA214773.
Identification & Billing
- RxCUI: 1307427 - sildenafil 10 MG in 1 mL Oral Suspension
- RxCUI: 1307427 - sildenafil 10 MG/ML Oral Suspension
- RxCUI: 1307427 - sildenafil (as sildenafil citrate) 10 MG/ML Powder for Oral Suspension
- RxCUI: 1307427 - sildenafil 10 MG per 1 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59651 - Aurobindo Pharma Limited
- 59651-420 - Sildenafil Citrate
- 59651-420-11 - 1 BOTTLE in 1 CARTON / 112 mL in 1 BOTTLE
- 59651-420 - Sildenafil Citrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59651-420-11 identifies a specific commercial package of 1 bottle in 1 carton / 112 ml in 1 bottle of Sildenafil Citrate, a human prescription drug labeled by Aurobindo Pharma Limited. This powder, for suspension is formulated for oral use and contains sildenafil citrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurobindo Pharma Limited on December 23, 2022. The current certification is valid through December 31, 2027.
How is this Aurobindo Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59651042011. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 112 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.